What Does It Take to Synergistically Combine Sub-Potent Natural Products into Drug-Level Potent Combinations?

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Qin, Chu ^a,b,c,d   Tan, Kai Leng ^c   Zhang, Cun Long ^a,b   Tan, Chun Yan ^a,b   Chen, Yu Zong ^a,b,c   Jiang, Yu Yang ^a,b  

^a Tsinghua University   (China)

^b TSINGHUA UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; INDIRUBIN; NATURAL PRODUCT; TANSHINONE IIA; TETRAARSENIC TETRASULFIDE; THEAFLAVIN; THEAFLAVIN 3 MONOGALLATE; THEAFLAVIN 3' MONOGALLATE; THEAFLAVIN 3,3' DIGALLATE; THEAFLAVIN 3,3' MONOGALLATE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOAVAILABILITY; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG POTENTIATION; GENETIC VARIABILITY; GROWTH INHIBITION; HUMAN; IC 50; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; NONHUMAN; PROBABILITY; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AGENTS; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS;

EID: 84870383599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049969     Document Type: Article

References (60)

1. Molinski TF, Dalisay DS, Lievens SL, Saludes JP, (2009) Drug development from marine natural products. Nat Rev Drug Discov 8: 69-85.
2. Li JW, Vederas JC, (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165.
3. Newman DJ, Cragg GM, (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477.
4. Zhu F, Qin C, Tao L, Liu X, Shi Z, et al. (2011) Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A 108: 12943-12948.
5. Junio HA, Sy-Cordero AA, Ettefagh KA, Burns JT, Micko KT, et al. (2011) Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis). J Nat Prod 74: 1621-1629.
6. Gertsch J, (2011) Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med 77: 1086-1098.
7. Shabbir M, Love J, Montgomery B, (2008) Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer. Oncol Rep 19: 831-835.
8. Ma XH, Zheng CJ, Han LY, Xie B, Jia J, et al. (2009) Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. Drug Discov Today 14: 579-588.
9. Cochrane ZR, Gregory P, Wilson A (2011) Quality of natural product clinical trials: a comparison of those published in alternative medicine versus conventional medicine journals. J Diet Suppl 8: 135-143.
10. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, et al. (1998) Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575.
11. Cordell GA, Colvard MD, (2012) Natural products and traditional medicine: turning on a paradigm. J Nat Prod 75: 514-525.
12. Jia J, Zhu F, Ma X, Cao Z, Li Y, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111-128.
13. Zimmermann GR, Lehar J, Keith CT, (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42.
14. Kong DX, Jiang YY, Zhang HY, (2010) Marine natural products as sources of novel scaffolds: achievement and concern. Drug Discov Today 15: 884-886.
15. Kaiser J, (2011) Combining targeted drugs to stop resistant tumors. Science 331: 1542-1545.
16. Lewith GT, Hyland ME, Shaw S, (2002) Do attitudes toward and beliefs about complementary medicine affect treatment outcomes? American Journal of Public Health 92: 1604-1606.
17. Barker Bausell R, (2009) Are positive alternative medical therapy trials credible?: Evidence from four high-impact medical journals. Eval Health Prof 32: 349-369.
18. Staud R, (2011) Effectiveness of CAM therapy: understanding the evidence. Rheum Dis Clin North Am 37: 9-17.
19. Williamson EM, (2001) Synergy and other interactions in phytomedicines. Phytomedicine 8: 401-409.
20. Dinan L, Bourne PC, Meng Y, Sarker SD, Tolentino RB, et al. (2001) Assessment of natural products in the Drosophila melanogaster B(II) cell bioassay for ecdysteroid agonist and antagonist activities. Cell Mol Life Sci 58: 321-342.
21. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K, (2000) Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor. Proceedings of the National Academy of Sciences of the United States of America 97: 1433-1437.
22. Wagner H, (2011) Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia 82: 34-37.
23. Fantin B, Leggett J, Ebert S, Craig WA, (1991) Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 35: 1413-1422.
24. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84: 1424-1431.
25. Shoemaker RH, (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
26. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
27. Kumar N, Afeyan R, Kim HD, Lauffenburger DA (2008) Multi-Pathway Model Enables Prediction of Kinase Inhibitor Cross-Talk Effects on Migration of Her2-Overexpressing Mammary Epithelial Cells. Mol Pharmacol.
28. Xiong H, Choe Y, (2008) Dynamical pathway analysis. BMC Syst Biol 2: 9.
29. Sivachenko A, Kalinin A, Yuryev A, (2006) Pathway analysis for design of promiscuous drugs and selective drug mixtures. Curr Drug Discov Technol 3: 269-277.
30. Kim HS, Fay JC, (2007) Genetic variation in the cysteine biosynthesis pathway causes sensitivity to pharmacological compounds. Proc Natl Acad Sci U S A 104: 19387-19391.
31. Carvalho-Netto EF, Markham C, Blanchard DC, Nunes-de-Souza RL, Blanchard RJ, (2006) Physical environment modulates the behavioral responses induced by chemical stimulation of dorsal periaqueductal gray in mice. Pharmacol Biochem Behav 85: 140-147.
32. Yang H, Yang T, Baur JA, Perez E, Matsui T, et al. (2007) Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130: 1095-1107.
33. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, et al. (2008) Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors. J Clin Oncol.
34. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. (2012) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 40: D13-25.
35. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-1136.
36. Oprea TI, Bologa CG, Boyer S, Curpan RF, Glen RC, et al. (2009) A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol 5: 441-447.
37. MacIndoe JH, Woods GR, Etre LA, Covey DF, (1982) Comparative studies of aromatase inhibitors in cultured human breast cancer cells. Cancer Res 42: 3378s-3381s.
38. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, et al. (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24: 22-32.
39. Hayashi K, Shimura K, Makino T, Mizukami H, (2010) Comparison of the contents of kampo decoctions containing ephedra herb when prepared simply or by re-boiling according to the traditional theory. J Nat Med 64: 70-74.
40. Zhou XM, Lu CN, Qi WB, Ma YJ, Tang YZ, et al. (2011) In vivo anti-avian influenza virus activity of Qingkailing and Shuanghuanglian Orals. Chin. Tradit. Herb Drugs 42: 1351-1356.
41. Li LJ, Wang JY, Wang Y, Wang LJ, Wang HY, et al. (2005) Anti-Virus Activities of the Extract and Effective Components Isolated from Senecio Cannabifolius Less. Chin J Basic Med Tradit Chin Med 11: 585-587.
42. Csermely P, Agoston V, Pongor S, (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178-182.
43. Xie L, Evangelidis T, Bourne PE, (2011) Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol 7: e1002037.
44. Papp B, Pal C, Hurst LD, (2004) Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast. Nature 429: 661-664.
45. Pilpel Y, Sudarsanam P, Church GM, (2001) Identifying regulatory networks by combinatorial analysis of promoter elements. Nat Genet 29: 153-159.
46. Muller R, (2004) Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer Res Clin Oncol 130: 429-444.
47. Sergina NV, Rausch M, Wang D, Blair J, Hann B, et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445: 437-441.
48. Tong X, Li A, Zhang Z, Duan J, Chen X, et al. (2004) TCM treatment of infectious atypical pneumonia-a report of 16 cases. J Tradit Chin Med 24: 266-269.
49. Zhang GG, Lee W, Bausell B, Lao L, Handwerger B, et al. (2005) Variability in the traditional Chinese medicine (TCM) diagnoses and herbal prescriptions provided by three TCM practitioners for 40 patients with rheumatoid arthritis. J Altern Complement Med 11: 415-421.
50. Larder BA, Kemp SD, Harrigan PR, (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269: 696-699.
51. Dancey JE, Chen HX, (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5: 649-659.
52. Silver LL, (2007) Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6: 41-55.
53. Chiu PH, Hsieh HY, Wang SC, (2012) Prescriptions of traditional Chinese medicine are specific to cancer types and adjustable to temperature changes. PLoS One 7: e31648.
54. Efferth T, (2010) Personalized cancer medicine: from molecular diagnostics to targeted therapy with natural products. Planta Med 76: 1143-1154.
55. Harvey AL, Cree IA, (2010) High-throughput screening of natural products for cancer therapy. Planta Med 76: 1080-1086.
56. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A, (2006) The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol 34: 1670-1679.
57. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.
58. Overall CM, Kleifeld O, (2006) Tumour microenvironment- opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239.
59. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, et al. (2005) Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 65: 10524-10535.
60. Thanou M, Verhoef JC, Junginger HE, (2001) Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 52: 117-126.